A Phase 3 interventional study of retatrutide and tirzepatide in adults with fatty liver disease

Recruiting Phase 3 NCT07165028

Study Description

SYNERGY-Outcomes: A study testing two medications to prevent serious liver complications in people with metabolic fatty liver disease

Study Details

Registry ID:
NCT07165028
Conditions:
Metabolic Dysfunction-Associated Steatotic Liver Disease
Phase:
Phase 3
Target Enrollment:
4,500 participants
Start Date:
Healthy Volunteers:
No

Study Locations (586 sites)

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →